Lonza Group AG

Lonza proposes Pearl Huang for election at the annual general meeting in May 2027; if elected, she is to join the strategy and innovation committee and the remuneration committee. Huang currently serves on the boards of Waters and BB Biotech and previously held leadership roles at Roche, GSK and Merck. Angelica Kohlmann and Christoph Mäder will not stand for re-election in 2027; Lonza cites a planned renewal of the board as the reason. » Mere på finanzen.net

Lonza is expanding its US presence with a new facility for the commercial manufacture of spray-dried active ingredient dispersions in Bend, Oregon, due to start operations in 2029. The technology improves solubility and bioavailability of poorly soluble drugs and responds to growing demand from more complex drug development. The project is expected to create more than 80 jobs, strengthen proximity to key customers and boost regional supply‑chain resilience; Lonza calls the investment "significant" but did not disclose a concrete amount. » Mere på finanzen.net

Lonza shares rose 3.1 percent after the company announced an expansion of its production capacity and a deepened strategic collaboration with a leading US biopharma company. The news pushed on gains from the previous day, while the Swiss market as a whole pulled back amid geopolitical concerns and declines in heavyweights such as Roche and Novartis. » Mere på finanzen.net

Lonza reported a significant expansion of its strategic partnership with a US biopharma company that could be worth several billion CHF in total. The agreement covers commercial production of two additional biologics programs, options for two more programs, and the expansion of the Swiss site to increase production capacity. The news reinforces Lonza’s focus on high-value CDMO services after the sale of its capsules and health ingredients business and pushed the stock up about 2.2% to CHF 557.6; half-year results are expected on July 22. » Mere på de.investing.com

Lonza is expanding production capacity for payload linkers at its Visp site, central components of antibody-drug conjugates (ADCs). The move is aimed at increasing manufacturing capacity for ADC components and securing supply to partners in the biopharma industry. » Mere på finanzen.net